Clinical Trial

Intrathecal Dual Checkpoint Inhibitor (PD-1 and CTLA-4) in Combination With Pemetrexed for Leptomeningeal Metastasis

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This phase I/II study is to evaluate the recommended dose, safety, feasibility, and therapeutic response of intrathecal dual checkpoint inhibitor (targeting PD-1 and CTLA-4 with QL1706) in combination with pemetrexed in patients with leptomeningeal metastasis.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-02-01; most recent amendment 2026-07-19.
Status change: Recruiting → Active, Not Recruiting 2026-07-19
Status change: Not Yet Recruiting → Recruiting 2025-03-24
Trial Details
NCT Number NCT06809530
Lead Sponsor Guangzhou Medical University
Conditions Leptomeningeal Metastasis, Pemetrexed, PD-1 Inhibitor, CTLA4, Solid Tumors
Enrollment 34 participants
Start Date 2025-03-17
Primary Completion 2026-12-01 (estimated)
Study Completion 2027-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-21